Your browser doesn't support javascript.
loading
The effect of SGLT2 inhibitors and GLP1 receptor agonists on arterial stiffness: A meta-analysis of randomized controlled trials.
Rizos, Evangelos C; Tagkas, Christos F; Asimakopoulos, Alexandros-Georgios I; Tsimihodimos, Vasileios; Anastasiou, Georgia; Rizzo, Manfredi; Agouridis, Aris P; Ntzani, Evangelia E.
Afiliação
  • Rizos EC; School of Health Sciences, University of Ioannina, Ioannina, Greece. Electronic address: vagrizos@uoi.gr.
  • Tagkas CF; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
  • Asimakopoulos AI; Department of Primary Education, University of Ioannina, Ioannina, Greece.
  • Tsimihodimos V; Department of Internal Medicine, University hospital of Ioannina, Ioannina, Greece.
  • Anastasiou G; Department of Internal Medicine, University hospital of Ioannina, Ioannina, Greece.
  • Rizzo M; School of Medicine, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Palermo, Italy; College of Medicine, Mohammed Bin Rashid University (MBRU), Dubai, United Arab Emirates.
  • Agouridis AP; School of Medicine, European University Cyprus, Nicosia, Cyprus; Department of Internal Medicine, German Oncology Center, Limassol, Cyprus.
  • Ntzani EE; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece; Center for Evidence-Based Medicine, Department of Health Services, Policy and Practice, School of Public Health, Brown University, Providence, RI, USA.
J Diabetes Complications ; 38(7): 108781, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38833853
ABSTRACT

BACKGROUND:

Pulse wave velocity (PWV) and augmentation index (AIx) are indices used to assess arterial stiffness. We evaluated the effect of sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) on arterial stiffness indices.

METHODS:

We searched PubMed (up to January 2024) for RCTs assessing the effect of SGLT2i or GLP1-RA on arterial stiffness with reporting outcomes PWV and AIx. Effect sizes of the included studies were expressed as weighted mean difference (WMD) and 95 % confidence interval. Subgroup analyses were performed based on comparator (placebo vs. active comparator), design (RCT vs. crossover), population (diabetic vs. all) and blindness (yes vs. no).

RESULTS:

A total of 19 studies (SGLT2i, 12 studies; GLP1-RA, 5 studies; SGLT2i/GLP1-RA combination, 2 studies) assessing 1212 participants were included. We did not find any statistically significant association between GLP1-RA or SGLT2i and PWV or AIx. None of the subgroup analyses showed any statistically significant result.

CONCLUSION:

No evidence of a favorable change in arterial stiffness indices (PWV, AIx) was found following the administration of SGLT2i or GLP1-RA.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto / Diabetes Mellitus Tipo 2 / Rigidez Vascular / Receptor do Peptídeo Semelhante ao Glucagon 1 / Inibidores do Transportador 2 de Sódio-Glicose Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto / Diabetes Mellitus Tipo 2 / Rigidez Vascular / Receptor do Peptídeo Semelhante ao Glucagon 1 / Inibidores do Transportador 2 de Sódio-Glicose Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article